Gallbladder and bile duct cancer enzyme

In 2019, around 35,750 cases of malignant tumors of the gallbladder and the biliary tract outside the liver were diagnosed across Europe. The proportion of men with biliary tract cancer outside the liver was 79 percent, which is significantly higher than in women with 60 percent.

Histologically, these are mainly adenocarcinomas. In the case of biliary tract diseases, around eleven percent were so-called Klatskin tumors.

Also, with malignant tumors of the bile, the risk of disease increases continuously with age. The risk of developing the disease during their lifetime is one in 190 women and one in 210 men.

The gallbladder and biliary tract cancer enzyme slows down the growth and spread of cancer cells in the organism.

Cancer cells use various strategies to bypass the body's natural immune defenses. To wander to other parts of the body undetected, they camouflage themselves with a cover made of an endogenous substance. However, the gallbladder and biliary tract cancer enzyme can recognize these cells and destroy them. This effectively prevents metastases.

Cancer cells can also form structures that the immune system classifies as harmful and destroys them. As a result, living cancer cells remain undetected and can multiply freely. This deception is also undermined by the gallbladder and biliary tract cancer enzyme, which splits these camouflaged structures.

We recommend taking one capsule twice a day.